ライフサイエンスコーパス: DNA vaccination

1 mice in vitro and in vivo after intradermal DNA vaccination.

2 anti-gp120 Abs under identical conditions of DNA vaccination.

3 ce to ErbB-2 which was partially overcome by DNA vaccination.

4 ctionality to plasmids for gene delivery and DNA vaccination.

5 ral immune responses to this glycoprotein by DNA vaccination.

6 istribution of isotypes than that seen after DNA vaccination.

7 ween innate and adaptive immunity in mucosal DNA vaccination.

8 role in the induction of immune responses by DNA vaccination.

9 de ligands, inhibition of Th1 cytokines, and DNA vaccination.

10 lts have important clinical implications for DNA vaccination.

11 noregulatory role for CD8+ T cells following DNA vaccination.

12 cross-priming method of immune induction by DNA vaccination.

13 lethal LCMV infections is achieved following DNA vaccination.

14 and Ag-specific immune responses elicited by DNA vaccination.

15 ffector phase of the Th1 response after LACK DNA vaccination.

16 or generating immune responses in mice after DNA vaccination.

17 fic antibody and CTL responses in mice after DNA vaccination.

18 as a particularly potent adjuvant for the gD DNA vaccination.

19 rt the use of IL-6 as a cytokine adjuvant in DNA vaccination.

20 n an IL-1beta/IL-18-independent manner after DNA vaccination.

21 hat systemic protection was achieved by LACK DNA vaccination.

22 ion of protective immune responses following DNA vaccination.

23 tion of AIDS virus-specific CTL responses by DNA vaccination.

24 n be delivered in vitro and in vivo by using DNA vaccination.

25 the potential of this strategy for enhancing DNA vaccination.

26 not be easily detectable directly after the DNA vaccination.

27 s vaccine candidates in mice and compared to DNA vaccination.

28 with either CD25 mAb to deplete Tregs and/or DNA vaccination.

29 e potential to tailor the immune response to DNA vaccination.

30 iral transmission when injected 5 days after DNA vaccination.

31 ll, CD4(+) T-cell, and antibody responses to DNA vaccination.

32 HIV-1 envelope (Env) glycoprotein induced by DNA vaccination.

33 ralizing antibodies, peptide antagonists and DNA vaccination.

34 fically for applications in gene therapy and DNA vaccination.

35 Only Treg depletion followed by neu DNA vaccination abrogated tolerance to neu, resulting in

36 tramer staining of in vitro stimulated PBMC, DNA vaccinations administered to the skin with the gene

37 Furthermore, TA99 enhances DNA vaccination against a distinct melanoma antigen, gp1

38 In conclusion, TA99 enhances DNA vaccination against both the target antigen Tyrp1 an

39 very little data describes the potential of DNA vaccination against CDAD.

40 emory CD8(+) T-cell response generated by gB-DNA vaccination against HSV.

41 with EGFP and the first report of successful DNA vaccination against M. avium.

42 Recent reports of successful DNA vaccination against Mycobacterium tuberculosis in sm

43 To improve DNA vaccination against Mycobacterium tuberculosis, we e

44 In this study, we used DNA vaccination against the MACV glycoprotein precursor

45 uction of anti-Tyrp1 CD8+T-cell responses to DNA vaccination against Tyrp1 as assessed by IFN-gamma E

46 from lethal HSV-2 challenge compared with gD DNA vaccination alone in both inbred and outbred mice.

47 before papilloma onset was lengthened by E6 DNA vaccination alone or to some extent by GM-CSF DNA in

48 ymphocytes compared to infiltrates following DNA vaccination alone.

49 pigs in which BCG vaccination was boosted by DNA vaccination, although this increase was not statisti

50 he immunogenicity and protective efficacy of DNA vaccination and allows for significant reduction of

51 When DNA vaccination and conventional ATRA therapy are combin

52 yer's patch as a promising target tissue for DNA vaccination and demonstrates the efficacy of gene gu

53 was no GVHD in HSCT recipients treated with DNA vaccination and donor leukocyte infusion.

54 on the innate immune mechanisms involved in DNA vaccination and further enrich our understanding on

55 sults support use of these growth factors in DNA vaccination and specifically indicate their applicab

56 egy combines the antigen-specific effects of DNA vaccination and the beneficial effects of local gene

57 After the DNA vaccinations and the first protein boost, a greater

58 ic strategies such as myoblast implantation, DNA vaccination, and gene therapy for various disease co

59 es support the importance of investigating a DNA vaccination approach for the immunologic control of

60 As a result, we turned instead to a DNA vaccination approach using a plasmid encoding the hs

61 whether cytotoxic T cell (CTL) responses to DNA vaccination are dependent upon MHC class II-restrict

62 an disease have shown that SCTs expressed by DNA vaccination are potent stimulators of cytotoxic T ly

63 This method can be combined with DNA vaccination as a novel strategy to provide both shor

64 Protective immunity is induced by CFP-10 DNA vaccination as measured by a CFU reduction in the lu

65 Here we show that DNA vaccination at birth results in the rapid induction

66 DNA vaccination based immunotargeting of xCT in mice cha

67 ine MCP-1 during the early phases of plasmid DNA vaccination because injecting the type II NKT cell-a

68 The fourth DNA vaccination boosted the immune responses.

69 DNA vaccination by Biojector(R) was well-tolerated and c

70 In conclusion, DNA vaccination by electroporation primed for TCR clonot

71 uggests that the tumor-protective effects of DNA vaccination can be largely attributed to idiotype-sp

72 These findings demonstrate that DNA vaccination can elicit protection against lentivirus

73 DNA vaccination can elicit the production of anti-tumor

74 mor regression induced by Treg depletion and DNA vaccination can exacerbate autoimmunity, which warra

75 DNA vaccination can induce both humoral and cellular imm

76 mediated immunity against malaria parasites; DNA vaccination can induce both types of effector respon

77 These results show for the first time that DNA vaccination can result in potent transmission-blocki

78 In heavily infected mice, DNA vaccinations can switch the immune response from one

79 we investigated the therapeutic potential of DNA vaccination combined with a potent HBV broadly neutr

80 w that TA99 improves therapeutic efficacy of DNA vaccination combined with adoptive T-cell transfer i

81 DNA vaccination combined with Mycobacterium bovis bacill

82 s was more frequent and was skewed following DNA vaccination compared to that of protein immunization

83 These data not only indicate that DNA vaccination could be a successful approach to protec

84 In addition, we assessed whether DNA vaccination could retard the growth of a secondary a

85 nduced a high total IgG response, but bb0405 DNA vaccination did not elicit antibody responses.

86 However, unlike BCG vaccination, MPB83 DNA vaccination did not protect challenged guinea pigs f

87 tide, implying that the responses induced by DNA vaccination differ quantitatively but not qualitativ

88 he type of memory T-cell response induced by DNA vaccination does not determine the type of response

89 infection with P. berghei ANKA 6 weeks after DNA vaccination elicited comparable anti-Pbs48/45 antibo

90 The combination of antibody treatment and DNA vaccination enhanced the recruitment of B and CD8+ T

91 As in patients with chronic HBV infection, DNA vaccination failed to generate T cells that cleared

92 In addition, HER-2/neu DNA vaccination followed by CTL analysis further showed

93 culated with four vaccinations of DNA or two DNA vaccinations, followed by two boosts of affinity-pur

94 t study we have evaluated the feasibility of DNA vaccination for the induction of CTL reactivity to f

95 experiment, rabbit groups were treated by E6 DNA vaccination, GM-CSF DNA inoculation, or a combinatio

96 Although DNA vaccination has been emerged as a potential immunoth

97 In other animal model systems, DNA vaccination has been used to protect animals against

98 DNA vaccination has been widely studied in several model

99 DNA vaccination has emerged as a powerful approach in th

100 These results demonstrate that DNA vaccination has potential as a new approach for cont

101 DNA vaccination has proved to be a generally applicable

102 that under conditions of natural challenge, DNA vaccination has the capacity to confer complete prot

103 Tumor-bearing mice treated with KGF and DNA vaccination have improved long-term survival and dec

104 ine, moxifloxacin, and, perhaps, therapeutic DNA vaccination have the potential to improve on the cur

105 g antibody responses to WNV were elicited by DNA vaccination in humans, including in older individual

106 to generate CTL responses following plasmid DNA vaccination in mice lacking both B7-1 and B7-2 could

107 ifficult to translate promising results from DNA vaccination in mice to larger animals and humans.

108 These results demonstrate that DNA vaccination in the absence of any heterologous boost

109 ted to Tyrp1 peptide in mice receiving gp100 DNA vaccination in the presence of TA99.

110 We report here that TA99 enhances Tyrp1 DNA vaccination in the treatment of B16 lung metastases,

111 Additionally, LNP-DNA vaccination in young pigs provides a valuable model

112 ther, we show that concurrent multiple-route DNA vaccinations induce strong cellular immunity, in add

113 DNA vaccination induced antibody to and T cell responses

114 p24CE DNA vaccination induced humoral immune responses similar

115 In parallel, we observed that EBOV-GP DNA vaccination induced long-term immune responses in ma

116 DNA vaccination-induced immune responses significantly d

117 Here, we show that a single neonatal DNA vaccination induces cellular and humoral immune resp

118 While recent studies have demonstrated that DNA vaccination induces potent CD8+ T cell memory in viv

119 we investigate whether the site and mode of DNA vaccination influences the quality of the cellular i

120 DNA vaccination is a novel immunization strategy that ha

121 DNA vaccination is a promising strategy to induce effect

122 DNA vaccination is a rapidly developing technology that

123 DNA vaccination is an attractive alternative for deliver

124 DNA vaccination is an effective means of eliciting both

125 DNA vaccination is an effective means of eliciting stron

126 We describe how DNA vaccination is being developed for use in commercial

127 sponse to both intramuscular and intradermal DNA vaccination is highly dependent upon the generation

128 Moreover, the induction of memory CTLp by DNA vaccination is independent of MHC class II molecules

129 demonstrate that for the parameters tested, DNA vaccination is indistinguishable from live virus inf

130 However, a major problem of DNA vaccination is its limited potency, because only a v

131 DNA vaccination is particularly useful for the induction

132 pparent that the immune response achieved by DNA vaccination is quite malleable, and can be manipulat

133 Epitope-specific DNA vaccination leads to powerful antitumor attack and c

134 Interestingly, we found that plasmid DNA vaccination led to high-frequency CTL responses spec

135 DNA vaccination lends itself well to increasing the amou

136 In contrast to strong responses after DNA vaccination, M84-specific CD8(+)-T-cell responses we

137 that transfected muscle cells at the site of DNA vaccination may contribute to the magnitude and/or d

138 Because DNA vaccination may directly transfect dendritic cells,

139 DNA vaccination may offer a new approach to Ag-specific

140 l grade products for use in gene therapy and DNA vaccination may require >90% of the plasmid to be in

141 hanism by which CD8+ T cells induced by LACK DNA vaccination mediate both short- and long-term protec

142 These data suggest that DNA vaccination merits further investigation as a potent

143 These results suggest that DNA vaccination might yield improved vaccines to replace

144 In contrast, by using a DNA vaccination model, to separate the events of vaccina

145 Using a DNA vaccination model, we determined that immunization w

146 ion, during the first days following plasmid DNA vaccination, NKT cells release IL-5 and MCP-1, leadi

147 DNA vaccination of hamsters with the HTNV M gene conferr

148 DNA vaccination of LMP2- and LMP7-deficient mice induced

149 d to a plasmid for Gag antigen alone (pGag), DNA vaccination of mice with pSPD-Gag-CD40L induced an i

150 oduced arenavirus neutralizing antibodies by DNA vaccination of rabbits with plasmids encoding the fu

151 DNA vaccination of rhesus monkeys with either the SEOV o

152 cination represents an approach for enabling DNA vaccination of the mucosa.

153 l TMEV infection to determine the effects of DNA vaccination on the course of TMEV-induced central ne

154 T cells primed by DNA vaccination or by infection exhibited similar cytoki

155 treatment of established AHR, we developed a DNA vaccination plasmid containing OVA cDNA fused to IL-

156 elin microarrays demonstrate that tolerizing DNA vaccination plus GpG-ODN further decreased anti-myel

157 tivated cells measured directly ex vivo, the DNA vaccination primes for both CD4(+) and CD8(+) T cell

158 Finally, pulmonary, but not i.m., plasmid DNA vaccination protected mice from a lethal recombinant

159 scale, low-cost vaccine production, moreover DNA vaccination, proteomics, adjuvant design and oral va

160 rategy for safe, reproducible, and pain-free DNA vaccination remains elusive.

161 DNA vaccination represents a novel strategy for inducing

162 Thus, expression of IRBP in the periphery by DNA vaccination results in tolerance that acts at least

163 DNA vaccination showed protective and therapeutic effica

164 f DNA-encoding Flt3L and GM-CSF before MSP1a DNA vaccination significantly increased the population o

165 intranasal injection of individual HuNAb or DNA vaccination significantly reduces infection in the l

166 Gene gun-mediated DNA vaccination stimulates an immune response characteri

167 p by DCS: In this study, we describe a novel DNA vaccination strategy to enhance uptake and presentat

168 and B-cell responses can be achieved by this DNA vaccination strategy.

169 to carbohydrate Ags, we describe results of DNA vaccination studies in mice using plasmids encoding

170 shed the protective response induced by LACK DNA vaccination, suggesting a role for CD8(+) T cells in

171 Antiidiotypic Abs induced by DNA vaccination supported in vitro complement-mediated c

172 DNA vaccination that can induce both cellular and humora

173 eover, the addition of GpG-ODN to tolerizing DNA vaccination therapy effectively reduced overall mean

174 nst a second antigen beyond that afforded by DNA vaccination through CpG motifs.

175 This technology promises to be useful for DNA vaccination to elicit CD8 T cells, in vivo study of

176 unt for this may be the selective ability of DNA vaccination to induce CD8+ IFN-gamma-producing T cel

177 Following DNA vaccination, transfected cells secreted vaccine prot

178 ted the influence of antigen targeting after DNA vaccination upon the induction of cellular immune re

179 DNA vaccination using cationic polymers as carriers has

180 s and P. falciparum, and delivered by either DNA vaccination, viral vector vaccines or as protein-in-

181 Importantly, Bla g 1 DNA vaccination was able to induce IL-10-secreting regul

182 The insulin B-chain DNA vaccination was effective through induction of regul

183 DNA vaccination was employed to study immune responses t

184 DNA vaccination was evaluated with the experimental muri

185 nerate CTL responses following plasmid gp120 DNA vaccination was fully reconstituted by coadministeri

186 N mice showed that the immunity conferred by DNA vaccination was haplotype dependent.

187 e protective immune response induced by LACK DNA vaccination was IL-12 dependent.

188 ral antigen expression in mouse muscle after DNA vaccination was substantially increased and prolonge

189 nation of local gene delivery and tolerizing DNA vaccination, we demonstrate that codelivery of the i

190 To explore the utility of DNA vaccination, we have constructed eukaryotic expressi

191 MV infections was conferred within 1 week of DNA vaccination, well before the peak of the CD8(+) T-ce

192 minantly IgG2a); no serological responses to DNA vaccination were observed in the absence of Salmonel

193 ytotoxic T-cell responses induced by plasmid DNA vaccination were reduced in Sting-deficient animals.

194 Three intramuscular DNA vaccinations were delivered biweekly via in vivo ele

195 reduces regulatory T-cell populations during DNA vaccination, whereas IL-12 increases this cellular s

196 esponses of the greatest magnitude after the DNA vaccinations, while the i.d. group exhibited the res

197 Here, we show that plasmid DNA vaccination with a cassette encoding antigen (OVA) a

198 Previously, we demonstrated that DNA vaccination with a plasmid expressing the SEOV M gen

199 We previously demonstrated that DNA vaccination with a pp89-expressing plasmid effective

200 ove on this strategy by combining xenogeneic DNA vaccination with an agonist anti-glucocorticoid-indu

201 In this study, we employed DNA vaccination with an immunologically optimized mouse

202 Our investigators have previously shown that DNA vaccination with antigen linked to calreticulin (CRT

203 the unfavorable response of male NOD mice to DNA vaccination with InsB chain.

204 We show here that after DNA vaccination with M84, a higher percentage of M84-spe

205 (ii) DNA vaccination with monomeric gp120-based antigens can

206 These results suggest that DNA vaccination with selected CMV genes may provide a sa

207 Consistent with this activity, DNA vaccination with Sendai virus NP induced a substanti

208 DNA vaccination with SmCT-SOD induced a mean of 39% prot

209 multiclade consensus HIV Gag plasmid during DNA vaccination with that of IL-12.

210 We compared the protective efficacy of LACK DNA vaccination with that of recombinant LACK protein in

211 We previously showed that DNA vaccination with the cottontail rabbit papillomaviru

212 DNA vaccination with the LAWD and IL-12 genes significan

213 DNA vaccination with the M3 gene, encoding an immune eva

214 l antibody responses were detected following DNA vaccination with the N-terminal domain of SERA, sugg

215 ave addressed the question of whether "naked DNA" vaccination with a eukaryotic expression vector (pc

216 llectively, these results show that a single DNA vaccination within hours or days of birth can induce